1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
  5. > High-Growth Diagnostic Testing Markets

High-Growth Diagnostic Testing Markets

  • January 2016
  • -
  • TriMark Publications
  • -
  • 355 pages

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

Table Of Contents

High-Growth Diagnostic Testing Markets
1. Overview 10
1.1 Statement of Report 10
1.2 Scope of This Report 11
1.3 Methodology 12
1.4 Executive Summary 13

2. Introduction to the High-Growth Testing Market 24
2.1 Introduction to the Global Diagnostic Market 24
2.2 General Areas with Potential for High-Growth Testing 24
2.3 Market Drivers in the High-Growth Diagnostics Testing Sector 26
2.4 Market Segments for High-Growth Testing 26
2.5 Key Players in the High-Growth Diagnostics Testing Segment 26
2.6 High-Growth Testing Sector Analysis 28

3. Hepatitis Serologic Markers and Nucleic Acid Testing 29
3.1 Hepatitis B Virus (HBV) 29
3.2 Major Suppliers of Hepatitis B Virus (HBV) Testing Products 37
3.3 Market Revenue Analysis 39
3.4 Hepatitis C Virus (HCV) Testing 40
3.5 Market Analysis 47
3.5.1 HCV Market Share 48

4. Human Papillomavirus (HPV) Testing 50
4.1 Overview 50
4.2 The Association of HPV and Cervical Cancer 51
4.3 The PAP Test 52
4.4 Current Laboratory Methods for HPV Detection 54
4.4.1 Direct-Probe Methods 54
4.4.2 Signal Amplification 54
4.4.3 Target Amplification 54
4.5 Assays for HPV 55
4.6 Market Revenue Analysis 62
4.6.1 North American Market 63
4.6.2 European Market 66
4.7 Market and Technology Trends 67
4.7.1 Market Trends 67
4.7.2 Technology Trends 68

5. HIV 69
5.1 Introduction to HIV/AIDS 69
5.2 Market Dynamics 72
5.2.1 Market Drivers 72
5.2.2 Market Restraints 72
5.2.3 Market Trends 73
5.2.4 Technology Trends 75
5.3 Review of Selected HIV Testing Devices 76
5.3.1 Instruments and MDx Reagents 76
5.4 Market Analysis 83
5.5 Competitor Activity 86
5.6 HIV Market Challenges and Strategic Recommendations 87
5.7 Insurance Coverage and Reimbursement 89

6. Infectious Disease Testing 90
6.1 Introduction to Infectious Disease Testing 90
6.2 Types of Diagnosis for Infectious Diseases 91
6.2.1 Microbial Culture 91
6.2.2 Microscopy 91
6.2.3 Biochemical Tests 91
6.2.4 Molecular Diagnostics 91
6.3 Diagnostic Platforms for Infectious Diseases 92
6.3.1 Centralized Laboratory Testing for Infectious Diseases 92
6.3.2 POC Testing for Infectious Diseases 92
6.4 Emerging Technologies 93
6.5 Qualitative Analysis 93
6.5.1 Market Drivers 93
6.5.2 Market Restraints 94
6.6 Streptococcus Testing 94
6.7 Chlamydia Testing 97
6.8 Mononucleosis 101
6.9 Gonorrhea 102
6.10 Influenza 107
6.11 Malaria 109
6.12 Tuberculosis 113
6.13 Methicillin-Resistant Staphylococcus Aureus (MRSA) 122
6.14 Market Revenue Analysis 125

7. Cardiac Markers 126
7.1 Market Overview 126
7.2 Cardiac Marker Tests 126
7.2.1 Creatine Kinase (CK) 126
7.2.2 Myoglobin 127
7.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 127
7.2.4 C-Reactive Protein (CRP) 127
7.2.5 Homocysteine 128
7.3 Emerging Markers 128
7.3.1 B-type Natriuretic Peptide (BNP) 128
7.3.2 Myeloperoxidase (MPO) 129
7.3.3 Ischemia Modified Albumin (IMA) 129
7.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 130
7.3.5 Fatty Acid-Binding Proteins (FABPs) 130
7.4 Qualitative Analysis 131
7.4.1 Market Drivers 131
7.4.2 Market Restraints 133
7.5 Specific Cardiac Conditions 134
7.5.1 Acute Myocardial Infarction 134
7.5.2 Heart Failure (BNP) 134
7.5.2.1 Market Overview 134
7.5.2.2 Commercial Assays for BNP and NT-proBNP 136
7.5.2.3 Clinical Applications of BNP 138
7.5.3 CRP 142
7.6 Pulmonary Embolism (D-dimer Test) 143
7.7 Key Players 143
7.8 Market Revenue Analysis 152

8. Cytogenetic Testing 155
8.1 Cancer Testing 156
8.2 Prenatal Testing and Cytogenetics 158
8.2.1 Cystic Fibrosis Testing 159
8.2.1.1 CF Testing Methodology 161
8.2.1.2 CF Screening Technology Summary 163

9. Cancer Biomarker Testing 164
9.1 Segment Overview 164
9.2 The Cancer Testing Market 165
9.3 Competition 167
9.4 Individual Markets 168
9.4.1 Cancer Pathology: Testing 168
9.4.1.1 Rare Cell/Micro Metastasis Detection 169
9.4.1.2 Cancer Pathology: High-Throughput Screening 169
9.4.1.3 Competition 171
9.4.1.4 Drivers 171
9.4.2 Breast Cancer 172
9.4.2.1 CA 15-3 173
9.4.2.2 CA 27-29 174
9.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes 174
9.4.2.4 Estrogen and Progesterone Receptor (ER and PR) 176
9.4.2.5 Human Epidermal Growth Factor Receptor 2 (HER-2) 178
9.4.2.6 Herceptin 179
9.4.2.7 p53 180
9.4.2.8 MammaPrint 180
9.4.2.9 Drivers for Breast Cancer Test Development 181
9.4.2.9.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends 181
9.4.2.9.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends 181
9.4.2.9.3 Breast Cancer Testing Assay Strategic Recommendations 182
9.4.3 Ovarian Cancer 182
9.4.3.1 Cancer Antigen 125 (CA 125) 183
9.4.3.2 BRCA1 and BRCA2 184
9.4.3.3 Epidermal Growth Factor Receptor (EGFR) 184
9.4.4 Cervical Cancer 185
9.4.4.1 Cervical Cancer Screening Tests 185
9.4.5 Colon Cancer DNA Testing 186
9.5 Pharmacogenomic Cancer Testing 188
9.6 Market Revenue Analysis 191

10. Substance Abuse Testing 193
10.1 Background to POC Substance Abuse Testing 193
10.2 Substance Abuse Test Types 199
10.2.1 Urine Substance/Drug Screening 199
10.2.2 Hair Tests for Substance Abuse and Screening 199
10.2.3 Blood Tests for Substance Abuse and Screening 200
10.2.4 Saliva Tests for Substance Abuse and Screening 200
10.2.5 Sweat Tests for Substance Abuse and Screening 200
10.3 Alcohol Abuse and Screening 200
10.4 Saliva Testing 201
10.5 Qualitative Analysis 201
10.5.1 Market Drivers 201
10.5.2 Market Restraints 202
10.6 Review of Selected POC Substance Abuse Analyzers 202
10.7 Review of Company Products 202
10.7.1 Alere 202
10.7.2 Abbott Diagnostics 202
10.7.3 BioScan Screening Systems, Inc. 202
10.7.4 American Bio Medica Corporation 203
10.7.5 Phamatech, Inc. 203
10.7.6 OraSure Technologies, Inc. 203
10.7.7 Alfa Scientific Designs, Inc. 203
10.7.8 Branan Medical 204

11. Vitamin D Diagnostic Testing 206
11.1 Market Revenue Analysis 210

12. Companion Diagnostics 211
12.1 Market Revenue Analysis 212

13. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 213
13.1 Summary Analysis of the Global IVD Market 213
13.2 Summary Analysis of the Global IVD High-Growth Market by Geographic Region 218
13.3 U.S.: Summary Analysis of the IVD High-Growth Market 219
13.3.1 Cardiac Markers 221
13.4 Europe: Summary Analysis of the IVD High-Growth Market 227
13.4.1 Summary of IVD High-Growth Market Europe 229
13.5 Brazil: Summary Analysis of the IVD High-Growth Market 234
13.5.1 Summary of IVD High-Growth Market Brazil 234
13.6 Russia: Summary Analysis of the IVD High-Growth Market 235
13.6.1 Summary of IVD High-Growth Market Russia 236
13.7 India: Summary Analysis of the IVD High-Growth Market 238
13.7.1 Summary of IVD High-Growth Market India 240
13.8 China: Summary Analysis of the IVD High-Growth Market 242
13.8.1 Summary of IVD High-Growth Market China 251
13.9 South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market 252
13.9.1 Japan 253
13.9.2 South Korea 256
13.9.3 Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia 256
13.9.4 Summary of IVD High-Growth Market Other Asia 258

14. Clinical Laboratory Genomics 260
14.1 Introduction 260
14.2 Clinical Laboratory Genomics Testing 261
14.3 Developments in Clinical Laboratory Genomics 262
14.3.1 Nucleic Acid Amplification Techniques 262
14.3.2 Chromosome Imaging 263
14.3.3 Genomics Technologies 263
14.3.4 Proteomics Technology 264
14.3.5 Current Pharmacogenomic Tests 264
14.3.6 Future Pharmacogenomic Testing 265

15. Cellular Imaging Cytopathology and Histopathology 267
15.1 Segment Overview 267
15.2 The Market 267
15.3 Market Drivers 269
15.4 Market Restraints 270
15.5 Cytology and Histology Technology Platforms 270
15.5.1 Cytology Screening Procedures and Pap Smear Technology 270
15.5.2 Histology 271
15.5.3 Market Drivers 272
15.5.4 ISH Staining 272
15.5.5 Special-Stains Staining 272
15.6 Third-Party Reimbursement 272

16. High-Growth Testing Diagnostic Trends 274
16.1 Genetic Testing 274
16.2 Quality Measures 274
16.3 Moderators of Growth 274
16.3.1 Diagnostics and the Aging Population 274
16.3.2 Individualized Medicine 274
16.3.3 Genetic Testing 274
16.4 Workforce Issues 275
16.5 Reimbursement 276
16.5.1 Cardiovascular 276
16.5.2 Screening for Diabetes 277
16.5.3 CPT Test Codes and Payment Amounts 278
16.6 Rapid Near-Patient Testing in Hospitals 280
16.7 Satellite Facilities 280
16.8 Regionalization of Laboratory Care 281
16.9 Requirements for High-Growth Testing 282
16.10 Clinical Laboratory Improvement Act (CLIA) 283

17. Important Technology Trends 286

18. Molecular Diagnostics a Major Diagnostic Technological Advance 289
18.1 Polymerase Chain Reaction (PCR)-Based Molecular Diagnostics 290
18.2 Micrarray Technologies and Molecular Diagnostics 291
18.3 Isothermal Amplification Technologies and Molecular Diagnostics 292
18.4 Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip) 292

19. Technology Platform Innovations in POCT 294
19.1 The Biggest New Opportunities in POCT 295
19.2 Latest POCT Technological Platforms 295
19.2.1 Device Miniaturization and Microfluidic Technologies 296
19.2.2 Minimally-Invasive and Non-Invasive POCT Technologies 296
19.2.3 Advances in Wireless Technologies 296
19.2.4 Automation of POCT 296
19.2.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing
Technologies) 297
19.2.6 Advances in Informatics Technologies 299
19.2.7 Pharmacogenetic Testing 299
19.2.8 Multi Assay Technologies in POCT 300
19.3 Developments in Key Technologies 300
19.3.1 Medical and Biological Sensors and Sensor Systems 300
19.3.2 Recent Biosensor Product Introductions and Latest Innovative Developments 301
19.3.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers 301
19.3.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments 302
19.4 Sensor Systems for Diagnostic Applications 303
19.5 Nanogen (The ELITech Group) Third Generation Point of Care Analyzer 305
19.6 Philips Development of Magnotech Technology 305
19.7 Quidel Corporation MChip, AVR Chip and F Chip 306
19.8 Sanofi-Aventis 306

20. Data Management and Connectivity 308
20.1 Wireless LANs 308
20.2 Connectivity Platforms 311
20.2.1 DataLink Data Management System 311
20.2.2 International Technidyne Corporation HEMOCHRON Signature Elite 314
20.2.3 Siemens Diagnostics RAPIDPoint 500 315
20.2.4 Alere Connect Products 315
20.2.5 Medical Implant Communications Service (MICS) 315
20.2.6 Conworx Technology 316
20.2.7 Alere Informatics 316
20.2.8 Medasys 316
20.2.9 NoemaLife 317
20.3 Advantages of Connectivity 317
20.3.1 Cost Benefit of POCT and IT Connectivity 317
20.3.2 Hospital Network Issues 318
20.4 Analyzer Connectivity Software Solutions 318

21. Biochips for Clinical Applications 320
21.1 Breast Cancer DNA Chips 327

22. Company Profiles 328
22.1 Abbott Laboratories 328
22.2 Alere, Inc. 331
22.3 Beckman Coulter (now part of Danaher) 335
22.4 Becton, Dickinson and Company 337
22.5 Biomerica, Inc. 339
22.6 Bio-Rad Laboratories, Inc. 339
22.7 Chembio Diagnostics, Inc. 340
22.8 Hologic Gen Probe 340
22.9 Johnson and Johnson 345
22.10 OraSure 345
22.11 QIAGEN N.V. 346
22.12 Quidel Corporation 349
22.13 Roche Diagnostics 353
22.14 Siemens Healthcare Diagnostics 356


INDEX OF FIGURES

Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2013 and 2018 18
Figure 1.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country, 2013 19
Figure 1.3: Company Market Share for IVD Testing Markets, 2013 20
Figure 3.1: Geographic Distribution of Chronic HBV Infection 30
Figure 3.2: Evolution of HBV Markers in Acute and Chronic Infection 36
Figure 3.3: U.S. Market Share of HCV Molecular Diagnostic Market, 2013 48
Figure 3.4: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2013 49
Figure 4.1: Hybrid Capture 2 (HC2) versus PCR—Analytical Sensitivity and Clinical Sensitivity 57
Figure 4.2: Basic Steps in Hybrid Capture 2 Technology 58
Figure 4.3: U.S. Market Share of HPV Molecular Diagnostic Market, 2014 62
Figure 4.4: Global Market Share (Excluding U.S.) of HPV Molecular Diagnostic Market, 2014 63
Figure 4.5: Market Share Estimates for Molecular Diagnostic HPV Testing, 2014 63
Figure 5.1: Ten Best Selling AIDS Drugs in the U.S., 2014 70
Figure 5.2: U.S. Rates for New HIV Cases, 2014 70
Figure 5.3: U.S. Rates for New HIV Cases in Men, 2014 71
Figure 5.4: U.S. Rates for New HIV Cases in Women, 2014 71
Figure 5.5: Estimated Market for Global HIV Molecular Diagnostic Testing, 2011-2020 83
Figure 5.6: Estimated Market for U.S. HIV Molecular Diagnostic Testing, 2011-2020 83
Figure 5.7: Market Share Viral Load HIV Molecular Diagnostic Testing 84
Figure 6.1: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2012 104
Figure 6.2: Mode of Action of Common Malaria RDT Format 111
Figure 6.3: Rate of Tuberculosis Cases by State/Area in the U.S., 2014 116
Figure 6.4: U.S.-Born Tuberculosis Cases by Ethnicity, 2014 117
Figure 6.5: FIND Pipeline for TB Diagnostics 119
Figure 13.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2013 and 2018 214
Figure 13.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country, 2013 215
Figure 13.3: Company Market Share for IVD Testing Markets, 2013 217
Figure 13.4: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2014 226
Figure 13.5: Cardiac Marker Market for Diagnostic Testing in Europe, 2010-2020 231
Figure 13.6: Indian Diagnostics Market Segments, 2011 239
Figure 13.7: The Chinese Healthcare System 243
Figure 20.1: The RALS Data Management System Connects to Most of the Major Instruments Used in
Point of Care 312
Figure 20.2: RALS-Freedom Point of Care and Critical Care Connectivity and Information Management
System 318


INDEX OF TABLES

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments 13
Table 1.2: Market Trends in the High-Growth Diagnostics Space 15
Table 1.3: Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018 18
Table 1.4: Top 15 Country Markets for IVD Testing, 2013 19
Table 1.5: Company Market Share for IVD Testing Markets, 2013 20
Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 21
Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018 21
Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 22
Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 22
Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections 33
Table 3.2: Lower Detection Limits of HBV DNA Assays 34
Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology 37
Table 3.4: Global Market for HBV Diagnostic Testing, 2014-2020 39
Table 3.5: U.S. Market for HBV Diagnostic Testing, 2014-2020 39
Table 3.6: Efficiency of Available HCV Screening Tests 44
Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C 45
Table 3.8: U.S. HCV Statistics 45
Table 3.9: Global Market for DNA HCV Diagnostic Testing, 2005-2013 47
Table 3.10: U.S. Market for DNA HCV Diagnostic Testing, 2005-2013 47
Table 3.11: Global Market for NAT HCV Diagnostic Testing, 2014-2020 47
Table 3.12: U.S. Market for NAT HCV Diagnostic Testing, 2014-2020 48
Table 3.13: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2013 48
Table 4.1: HPV Risk Factors 50
Table 4.2: HPV and Cervical Carcinoma 51
Table 4.3: Number of Pap Smears Performed by Country, 2014 53
Table 4.4: Qiagen's Digene HC2 High-Risk HPV DNA Test 56
Table 4.5: Commercially Available Molecular Diagnostic Products for HPV Assay 61
Table 4.6: Long-Term Trends in HPV Testing 62
Table 4.7: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share, 2014 62
Table 4.8: Global Market for HPV Molecular Diagnostic Testing, 2014-2020 67
Table 4.9: U.S. Market for HPV Molecular Diagnostic Testing, 2014-2020 67
Table 5.1: HIV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 72
Table 5.2: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact 72
Table 5.3: HIV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 72
Table 5.4: Drivers of Demand for HIV Diagnostic Testing 73
Table 5.5: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact 73
Table 5.6: Summary of Assays for HIV Viral Load Testing 76
Table 5.7: Commercially Available Molecular Diagnostic Products for HIV Assay 82
Table 5.8: Global Market for Molecular Diagnostic HIV Diagnostic Testing, 2014-2020 84
Table 5.9: U.S. Market for Molecular Diagnostic HIV Diagnostic Testing, 2014-2020 84
Table 5.10: Global Market for HIV Viral Load Diagnostic Testing, 2007-2013 85
Table 5.11: U.S. Market for HIV Viral Load Diagnostic Testing, 2007-2013 85
Table 5.12: Global Market for HIV Viral Load Diagnostic Testing, 2014-2020 85
Table 5.13: U.S. Market for HIV Viral Load Diagnostic Testing, 2014-2020 86
Table 5.14: Competitive Factors Related to HIV Tests 87
Table 6.1: Rapid Strep Tests on the Market 95
Table 6.2: U.S. Chlamydia Infection Rates, 1985-2012 98
Table 6.3: Rapid Tests for Chlamydia 99
Table 6.4: Rapid Tests for Gonorrhea 104
Table 6.5: Global Market for Tuberculosis Molecular Diagnostic Testing, 2005-2014 122
Table 6.6: U.S. Market for Tuberculosis Molecular Diagnostic Testing, 2005-2014 122
Table 6.7: Commercially Available Molecular Diagnostic Products for MRSA Assay 124
Table 6.8: Global Market for MRSA Diagnostic Testing, 2005-2014 125
Table 6.9: U.S. Market for MRSA Diagnostic Testing, 2005-2014 125
Table 7.1: Medication Chart for Cardiovascular Disease 131
Table 7.2: Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact 133
Table 7.3: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact 134
Table 7.4: BNP Clinical Characteristics 135
Table 7.5: FDA Approved BNP Assays 137
Table 7.6: FDA Approved NT-proBNP Assays 137
Table 7.7: BNP Clinical Characteristics 138
Table 7.8: Cardiovascular Risk Classification by CRP Level 142
Table 7.9: Cardiac Marker Markets by Country and Region, 2010-2020 153
Table 7.10: Cardiac Marker Markets by Country and Region, 2010-2020 153
Table 7.11: Total Global Cardiac Marker Market, 2010-2020 153
Table 8.1: Genetic Testing: Consequences and Challenges 159
Table 8.2: CF Carrier Risk by Ethnic Group 160
Table 8.3: Reasons for CF Testing 160
Table 8.4: CF Gene Detection Rates Vary by Ethnic Background 162
Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018 162
Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018 163
Table 9.1: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2014 166
Table 9.2: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2014 166
Table 9.3: Corporate Players Entering the Prostate Cancer Molecular Diagnostic Space 168
Table 9.4: Worldwide CA 15-3 Sales, 2009-2019 173
Table 9.5: TPA Marker Sensitivity 176
Table 9.6: Overview of ER/PR Testing and Response to Therapy 177
Table 9.7: Overview of HER2/neu and Herceptin 179
Table 9.8: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact 181
Table 9.9: Commercially Available Molecular Diagnostic Products for Ovarian Cancer Assay 183
Table 9.10: INFINITI Applications 191
Table 9.11: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018 192
Table 10.1: Stat Urine Testing Drug Recommendations 198
Table 11.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018 210
Table 13.1: Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018 213
Table 13.2: Top 15 Country Markets for IVD Testing, 2013 216
Table 13.3: Company Market Share for IVD Testing Markets, 2013 217
Table 13.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 218
Table 13.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 219
Table 13.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 219
Table 13.7: Summary of IVD High-Growth Market U.S., 2013 220
Table 13.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S.,
2008-2018 220
Table 13.9: U.S. Individual IVD High-Growth Markets Revenue Forecast 2008-2018 221
Table 13.10: Cardiac Markers in Clinical Use 222
Table 13.11: Cardiac Markers after Onset of Myocardial Infarction 223
Table 13.12: U.S. Cardiac Marker Market, 2010-2020 225
Table 13.13: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2014 226
Table 13.14: Market Share of Cardiac Marker Segment 227
Table 13.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe,
2008-2018 229
Table 13.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 230
Table 13.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 230
Table 13.18: Cardiac Marker Market for Diagnostic Testing in Europe, 2010-2020 231
Table 13.19: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil,
2008-2018 234
Table 13.20: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 235
Table 13.21: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 235
Table 13.22: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia,
2008-2018 237
Table 13.23: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 237
Table 13.24: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 238
Table 13.25: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India,
2008-2018 241
Table 13.26: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 241
Table 13.27: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 242
Table 13.28: Disease Burden in China: Urban and Rural 245
Table 13.29: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China,
2008-2018 251
Table 13.30: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 252
Table 13.31: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 252
Table 13.32: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia,
2008-2018 258
Table 13.33: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 259
Table 13.34: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
2008-2018 259
Table 15.1: Medicare National Minimum Payment Amounts for Cervical Pathology Procedures 273
Table 16.1: New CPT Test Codes Introduced in 2008 279
Table 19.1: Common Genotype Techniques 298
Table 20.1: Applications for Wireless LAN Technology 308
Table 20.2: Customized Reports Must Support CAP and JCAHO Requirements 312

Table 21.1: Biochip Revenues and Growth Rates by Application, 2012 and 2018 320
Table 21.2: Biochip Revenues and Growth Rates by Type, 2009 and 2015 321
Table 22.1: Drugs of Abuse Cut-off Levels for the TOX 340

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...

2016 Hematology and Flow Cytometry Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test, Technology Trends, Opportunities for Suppliers

2016 Hematology and Flow Cytometry Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test, Technology Trends, Opportunities for Suppliers

  • $ 33500
  • Industry report
  • October 2016
  • by Venture Planning Group

This 33-country survey from VPGMarketResearch.com contains over 900 pages, 380 tables and provides granular data and analysis not available elsewhere. The survey is designed to help current suppliers and ...

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

  • $ 30000
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 820 pages and 418 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.